Condition: ENSAT Stage I Adrenal Cortex Carcinoma · ENSAT Stage II Adrenal Cortex Carcinoma · ENSAT Stage III Adrenal Cortex Carcinoma · Sponsor: M.D. Anderson Cancer Center
This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high risk of coming back (recurrence). Cortisol can cause the growth of adrenocortical tumor cells. Antihormone therapy, such as mitotane, may lessen the amount of cortisol made by the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether mitotane alone or mitotane with cisplatin and etoposide after surgery works better in treating patients with adrenocortical carcinoma.
This description comes directly from the study's public registry record.
Jeena Varghese · 713-792-2841 · jvarghese@mdanderson.org
Always discuss trial participation with your own doctor first.
| University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan, United States | Recruiting |
| Siteman Cancer Center at Washington University | St Louis, Missouri, United States | Active Not Recruiting |
| M D Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Institut de Cancérologie de l'Ouest (ICO) | Angers, France | Active Not Recruiting |
| CHU Angers, Hôpital Larrey | Angers, France | Recruiting |
| CHU Besançon, Hôpital Jean Minjoz | Besançon, France | Recruiting |
| CHU Brest, Hôpital La Cavale Blanche | Brest, France | Active Not Recruiting |
| Centre Georges François Leclerc | Dijon, France | Recruiting |
| Lyon HCL | Lyon, France | Recruiting |
| HCL Hôpital Louis Pradel | Lyon, France | Not Yet Recruiting |
| Marseille Hôpital Nord | Marseille, France | Recruiting |
| Marseille Hôpital de la Conception | Marseille, France | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03583710